Andrew Davies retweeted
Thoughtful @JCO_ASCO editorial on Treatment of Hodgkin Lymphoma in Older Patients: "N-AVD should become the new standard...BrECADD is an alternative in very fit older adults where response-adapted treatment would be appropriate."
ascopubs.org/doi/full/10.120…
Andrew Davies retweeted
We’re bringing the UK's leading lymphoma experts straight to your screen for #LymphomaManagement 2025. Are you a registrar, consultant, specialist nurse, pharmacist or other healthcare professional? Register now 👉 lymphoma-action.org.uk/event…
#LymSM #Lymphoma @tobyeyre82 @graham74GC
Andrew Davies retweeted
Just released BSH R/R LBCL guideline with updated guidance on this rapidly evolving field. onlinelibrary.wiley.com/doi/…
Andrew Davies retweeted
Davies et al
ash.confex.com/ash/2022/webp…
RCT
for ABC (by GEP) DLBCL, Bortezomib+RCHOP21 associated with ⬆️PFS
Also ⬆️OS intriguingly, however not powered for OS:
thelancet.com/action/showPdf…
Looking fwd to this presentation at #ASH22
#lymsm @graham74GC @AndyD1036
@ASH_hematology







